1. Home
  2. EXK vs NAMS Comparison

EXK vs NAMS Comparison

Compare EXK & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endeavour Silver Corporation (Canada)

EXK

Endeavour Silver Corporation (Canada)

HOLD

Current Price

$10.01

Market Cap

2.8B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$38.50

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXK
NAMS
Founded
1981
2019
Country
Canada
Netherlands
Employees
N/A
100
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.3B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
EXK
NAMS
Price
$10.01
$38.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$13.94
$46.75
AVG Volume (30 Days)
7.2M
938.9K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.59
$17.96
Revenue Next Year
$17.61
$540.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.23
$16.79
52 Week High
$15.15
$42.00

Technical Indicators

Market Signals
Indicator
EXK
NAMS
Relative Strength Index (RSI) 54.70 69.61
Support Level $8.33 $34.05
Resistance Level $10.40 $41.40
Average True Range (ATR) 0.56 2.20
MACD 0.09 0.62
Stochastic Oscillator 51.93 77.33

Price Performance

Historical Comparison
EXK
NAMS

About EXK Endeavour Silver Corporation (Canada)

Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: